Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding.

Nature·2026
Same author

Toward a Random Background for Ligand Optimization.

bioRxiv : the preprint server for biology·2026
Same author

Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding.

bioRxiv : the preprint server for biology·2026
Same author

Two decades of PARP inhibitor synthetic lethality in cancer.

Nature·2026
Same author

Comparative sequence analysis of the mouse pseudoautosomal region from three inbred strains reveals it to be the most rapidly evolving 'chromosome'.

Proceedings of the Japan Academy. Series B, Physical and biological sciences·2026
Same author

Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.

British journal of cancer·2026
Same journal

Estrobolome and the Endocrine-Microbiome Axis in Breast and Endometrial Carcinogenesis.

Critical reviews in oncology/hematology·2026
Same journal

Remodeling the Immune Microenvironment: Engineering IL-2 Variants to Overcome Clinical Bottlenecks in PD-1 Inhibitor plus Chemotherapy.

Critical reviews in oncology/hematology·2026
Same journal

Neoadjuvant Immunotherapy in Melanoma: From Pathologic Response to Response-Adapted Management.

Critical reviews in oncology/hematology·2026
Same journal

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026
Same journal

Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

Critical reviews in oncology/hematology·2026
Same journal

Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

Critical reviews in oncology/hematology·2026
See all related articles

Related Experiment Video

Updated: Mar 10, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.6K

PARP inhibitor combination therapy.

Amy Dréan1, Christopher J Lord1, Alan Ashworth2

  • 1The CRUK Gene Function Laboratory, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.

Critical Reviews in Oncology/Hematology
|December 10, 2016
PubMed
Summary
This summary is machine-generated.

Olaparib, the first Poly(ADP-ribose) polymerase (PARP) inhibitor, targets BRCA-mutated cancers. Combining PARP inhibitors with other therapies shows promise, with ongoing research into their clinical utility and future challenges.

Keywords:
BRCA1BRCA2Drug combinationsPARP inhibitor

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K
Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

40.0K

Related Experiment Videos

Last Updated: Mar 10, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.6K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K
Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

40.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Olaparib, the first Poly(ADP-ribose) polymerase (PARP) inhibitor, was approved in 2014 for cancer treatment.
  • PARP inhibitors exploit synthetic lethality to target tumors with BRCA1/BRCA2 mutations when used as single agents.
  • PARP inhibition demonstrates potential when combined with other therapeutic modalities.

Purpose of the Study:

  • To review preclinical and clinical evidence supporting the use of PARP inhibitor combinations.
  • To discuss the future prospects and challenges associated with combinatorial PARP inhibitor therapies.

Main Methods:

  • Literature review of preclinical studies on PARP inhibitor combinations.
  • Analysis of clinical trial data for PARP inhibitor combination therapies.
  • Discussion of emerging trends and obstacles in the field.

Main Results:

  • Preclinical data support the efficacy of various PARP inhibitor combinations.
  • Clinical evidence indicates promising outcomes for certain combination strategies.
  • Several challenges remain, including toxicity management and patient selection.

Conclusions:

  • PARP inhibitor combinations represent a promising therapeutic strategy in oncology.
  • Further research is needed to optimize combination regimens and overcome existing challenges.
  • Future directions include exploring novel combinations and predictive biomarkers.